Scinai Immunotherapeutics Ltd

詳細情報 Scinai Immunotherapeutics Ltd 企業名

Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

企業情報

企業コードSCNI

会社名Scinai Immunotherapeutics Ltd

上場日Jun 07, 2007

最高経営責任者「CEO」Mr. Amir Reichman

従業員数31

証券種類Depository Receipt

決算期末Jun 07

本社所在地Jerusalem Biopark, 2Nd Floor

都市JERUSALEM

証券取引所NASDAQ Capital Market Consolidated

国Israel

郵便番号00000

電話番号97289302529

ウェブサイトhttps://www.scinai.com/

企業コードSCNI

上場日Jun 07, 2007

最高経営責任者「CEO」Mr. Amir Reichman

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Amir Reichman

Chief Executive Officer, Director

8.08K

+236.54%

Dr. Tamar Ben-Yedidia

Chief Scientific Officer

1.35K

--

Mr. Elad Mark

Chief Operating Officer

1.27K

--

Mr. Uri Ben-Or, CPA

Chief Financial Officer

276.00

--

Mr. Adi Raviv

External Director

50.00

+51.52%

Prof. Avner Rotman

Director

50.00

-26.47%

Dr. Yael Margolin

External Director

50.00

+51.52%

Mr. Samuel J. Moed

Director

--

Mr. Joshua Phillipson

Investor Relations

--

Dr. Morris C. Laster, M.D.

Independent Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Amir Reichman

Chief Executive Officer, Director

8.08K

+236.54%

Dr. Tamar Ben-Yedidia

Chief Scientific Officer

1.35K

--

Mr. Elad Mark

Chief Operating Officer

1.27K

--

Mr. Uri Ben-Or, CPA

Chief Financial Officer

276.00

--

Mr. Adi Raviv

External Director

50.00

+51.52%

Prof. Avner Rotman

Director

50.00

-26.47%

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Wed, May 28

株主統計

種類

株主統計

比率

Yorkville Advisors Global, LP.

10.93%

LCK JNK 1 LLC

9.47%

Stone (Daniel E)

7.32%

Armistice Capital LLC

5.25%

Abalone Asset Management Ltd.

4.99%

Other

62.04%

株主統計

比率

Yorkville Advisors Global, LP.

10.93%

LCK JNK 1 LLC

9.47%

Stone (Daniel E)

7.32%

Armistice Capital LLC

5.25%

Abalone Asset Management Ltd.

4.99%

Other

62.04%

種類

株主統計

比率

Investment Advisor/Hedge Fund

14.34%

Corporation

9.47%

Individual Investor

8.75%

Investment Advisor

6.93%

Hedge Fund

5.25%

Research Firm

0.02%

Other

55.24%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

32

381.87K

44.77%

+269.77K

2025Q1

34

424.61K

49.78%

+268.71K

2024Q4

29

225.02K

26.38%

+113.05K

2024Q3

33

172.68K

20.39%

+41.77K

2024Q2

34

145.50K

9.79%

-4.50K

2024Q1

37

164.38K

100.97%

+8.82K

2023Q4

39

169.63K

48.24%

+28.24K

2023Q3

42

134.35K

45.97%

+54.60K

2023Q2

41

94.79K

37.87%

-787.00

2023Q1

43

111.61K

43.64%

+31.95K

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Yorkville Advisors Global, LP.

93.27K

10.93%

+93.27K

--

Mar 24, 2025

LCK JNK 1 LLC

80.76K

9.47%

+80.76K

--

Feb 09, 2025

Stone (Daniel E)

62.40K

7.32%

--

Dec 31, 2024

Armistice Capital LLC

44.80K

5.25%

+44.80K

--

Sep 30, 2024

Abalone Asset Management Ltd.

42.54K

4.99%

+24.54K

+136.35%

Jun 30, 2024

Sabby Management, LLC

29.05K

3.41%

+29.05K

--

Dec 31, 2024

UBS Financial Services, Inc.

14.93K

1.75%

-8.56K

-36.43%

Mar 31, 2025

Reichman (Amir)

8.08K

0.95%

+5.68K

+236.54%

Mar 31, 2025

Rhumbline Advisers Ltd. Partnership

1.57K

0.18%

-86.00

-5.20%

Mar 31, 2025

Ben-Yedidia (Tamar)

1.35K

0.16%

+1.35K

--

Mar 31, 2025

詳細を見る

1.530USD

Scinai Immunotherapeutics Ltd

1.530

概要

企業名

金融